SCHEMBL640063

SCHEMBL640063

S=c1[nH]cc(-c2ccc3c(c2)CCCC3)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 1/20 0.49
HDAC8 Q9BY41 1/20 0.46
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
MCL1 Q07820 1/20 0.44
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640250 0.97 KDM4E (0.49) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL28663639 0.71 CYP11B1 (0.61) KDM4EALDH1A1MAPTL3MBTL1NPC1
SCHEMBL638781 0.70 GFER (0.53) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL639509 0.69 KDM4E (0.47) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL640039 0.69 DCUN1D1 (0.48) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL4067927 0.68 CYP11B1 (0.51) ALDH1A1MAPTPOLBNPC1RAB9A
SCHEMBL3344780 0.67 GAA (0.64) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL3343038 0.67 GFER (0.64) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL3342194 0.67 KDM4E (0.64) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL638777 0.67 GFER (0.58) GFERKDM4EGAAHDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US claimed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US claimed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP claimed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO claimed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO claimed
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US disclosed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP disclosed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO disclosed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF TYR, TH, PAH GFER 2966/4885KDM4E 582/4885GAA 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.